title: Anti-inflammatory activity of telmisartan in rat models of experimentally-induced chronic inflammation: Comparative study with dexamethasone.
abstract: Recently, significant progress has been made through the application of peroxisome proliferator activated receptor-γ (PPAR-γ) agonists as anti-inflammatory drugs that are efficacious, relatively free of side effects, and can be used effectively for a long time. The present study was designed to evaluate the dose-response relationship of the anti-inflammatory activity of telmisartan in rat models of chronic inflammation. The study protocol includes four stages: First stage: 48 rats were allocated into eight groups, each containing six rats, for the study of the anti-inflammatory activity of different doses of telmisartan in rat model of formaldehyde-induced chronic inflammation. Second stage: six rats were used to study the anti-inflammatory activity of telmisartan (1.5 mg/kg) in combination with dexamethasone (0.5 mg/kg) in the same model. Third stage: 48 rats were allocated into eight groups, each containing six rats, for the study of the anti-inflammatory activity of telmisartan in rat model of cotton pellet-induced granuloma. Fourth stage: six rats were used to study the anti-inflammatory activity of telmisartan (1.5 mg/kg) when used as adjuvant with dexamethasone (0.5 mg/kg) in the same model. Telmisartan in a dose-dependent pattern (0.1, 0.2. 0.4, 0.6, 1.5, 3 mg/kg) significantly suppressed inflammation in rat models of formaldehyde-induced chronic inflammation and cotton pellet-induced granuloma. When combined with dexamethasone, telmisartan (1.5 mg/kg body weight) significantly suppressed inflammation in both models, which is significantly higher than all of the effects produced by other approaches of treatment when telmisartan used alone. In conclusion, telmisartan decreased formaldehyde-induced chronic inflammation and cotton-pellet induced granuloma in rats in a dose-dependent pattern. Therefore, it may be considered as a potential treatment for chronic inflammatory conditions in human.
authors: Department of Pharmacology, College of Pharmacy, University of Basrah, Iraq.
authors: Waleed K G
authors: WK
authors: Al-Hejjaj
authors: Intesar T
authors: IT
authors: Numan
authors: Raghdan Z
authors: RZ
authors: Al-Sa'ad
authors: Saad A
authors: SA
authors: Hussain
keywords: Chronic inflammation; PPARγ; Telmisartan
references: Biochem Biophys Res Commun. 1999 Jan 27;254(3):582-6
references: 9920782
references: Cardiovasc Res. 2006 Oct 1;72(1):184-90
references: 16938288
references: Hypertension. 2008 Jul;52(1):51-6
references: 18474831
references: Int J Cardiol. 2006 Oct 26;113(1):86-91
references: 16891009
references: Atherosclerosis. 2008 Aug;199(2):295-303
references: 18093593
references: BMC Complement Altern Med. 2008 Jun 06;8:27
references: 18538006
references: Dig Dis Sci. 2007 Dec;52(12):3455-64
references: 17410441
references: Pharmazie. 2009 Sep;64(9):590-4
references: 19827301
references: Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2252-9
references: 16888236
references: J Immunol. 2005 Oct 15;175(8):4948-55
references: 16210596
references: Hypertension. 2004 May;43(5):993-1002
references: 15007034
references: J Am Pharm Assoc Am Pharm Assoc. 1957 Sep;46(9):515-9
references: 13491439
references: Eur J Pharmacol. 2009 May 1;609(1-3):105-12
references: 19292980
references: Expert Rev Cardiovasc Ther. 2006 Sep;4(5):615-29
references: 17081084
references: Ann N Y Acad Sci. 2008 Dec;1148:360-6
references: 19120129
references: J Pharm Pharmacol. 2001 Nov;53(11):1505-14
references: 11732753
references: Diabetologia. 2006 Dec;49(12):3094-9
references: 17004092
references: Hypertension. 2009 May;53(5):798-804
references: 19289654
references: Atherosclerosis. 2006 Jun;186(2):402-10
references: 16157344
references: J Neurosci. 1996 Aug 1;16(15):4742-8
references: 8764661
references: Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1487-94
references: 11704601
references: Circulation. 2004 May 4;109(17):2054-7
references: 15117841